MIRA PHARMACEUTICALS, INC. 8-K

What Happened
MIRA Pharmaceuticals, Inc. announced on June 25, 2026 (via a press release attached as Exhibit 99.1 to an 8-K), new preclinical pharmacology results for Mira‑55, its cannabinoid analog in development for chronic inflammatory pain. The company reported that Mira‑55 did not produce the locomotor suppression or catalepsy typically seen with THC, produced only a modest reduction in body temperature that was not reversed by the CB1 antagonist rimonabant, and showed anxiolytic activity in an assay where rimonabant was anxiogenic. MIRA said these results, together with prior preclinical data (reported March 2026), support a pharmacological profile differentiated from THC as it advances an IND‑enabling program.

Key Details

• Filing: Form 8‑K, Item 7.01 (Regulation FD Disclosure); press release dated June 25, 2026 filed as Exhibit 99.1.
• Behavioral findings: Mira‑55 did not cause locomotor suppression or catalepsy (effects associated with THC).
• Mechanism signal: Mira‑55 caused modest hypothermia that was not reversed by rimonabant, suggesting a non‑classical CB1 agonist mechanism.
• Anxiolytic activity: Mira‑55 produced anxiolytic effects in an assay, contrasting with anxiogenic effects seen with rimonabant.

Why It Matters
For investors, these preclinical findings indicate Mira‑55 may offer therapeutic activity on cannabinoid pathways without some of THC’s known central nervous system liabilities (psychoactivity, catalepsy, strong locomotor effects). That differentiation could improve the drug’s safety and commercial prospects if confirmed in further studies. However, the data are preclinical only — MIRA notes additional receptor‑level characterization and IND‑enabling work are required before clinical trials, so development and regulatory risks remain.